Advertisement

Topics

Latest "Frederick County Office of Economic Development" News Stories

08:07 EDT 24th September 2018 | BioPortfolio

Here are the most relevant search results for "Frederick County Office of Economic Development" found in our extensive news archives from over 250 global news sources.

More Information about Frederick County Office of Economic Development on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Frederick County Office of Economic Development for you to read. Along with our medical data and news we also list Frederick County Office of Economic Development Clinical Trials, which are updated daily. BioPortfolio also has a large database of Frederick County Office of Economic Development Companies for you to search.

Showing "Frederick County Office Economic Development" News Articles 1–25 of 20,000+

Monday 24th September 2018

American Shared Hospital Services to Present at the Sidoti & Company Fall 2018 Conference

American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced that Chairman & Chief Executive Officer Ernest A. Bates, M.D. and Chief Operating & Financial Officer Craig K. Tagawa will present at the Sidoti ...


New Study Reveals the Importance of Active-DHA in the Developing Brain

New research published in PLOS Biology unleashes possibilities for new innovations to support brain health Vanteres, an innovative biotech company leveraging its biomedical research expertise to develop actively transported lysophospholipids, announces new evidence that demonstrates the critical role of LPC-DHA in normal fetal and infant brain d...

Elanco Announces Full Exercise of Additional Stock, Sets Date for Q3 Earnings

Elanco announces the underwriters of its recent initial public offering have exercised in full their over-allotment option purchase an additional 9.435 million shares Elanco sets third quarter earnings call for Nov. 6, its first as an independent company Elanco to ring the New York Stock Exchange Opening Bell® ...


Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform on October 16, 2018 in New York City. The R&D Day will feature presentations by Ira Goldberg, M.D...

Dicerna to Participate in Two Upcoming Investor Conferences

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences in October. 2018 Cantor Fitzgerald Global Healthcare Conference...

LabCorp Statement on District Court Opinion in ACLA Lawsuit against HHS

LabCorp® (NYSE: LH) today issued the following statement regarding the decision from the U.S. District Court for the District of Columbia in ACLA v. Azar on Friday, Sept. 21, to dismiss the laboratory industry’s lawsuit to halt implementation of damaging cuts to Medicare reimbursement for lab testing: “We are deeply disappointed in the distri...

FARXIGA Achieved a Positive Result in the Phase III DECLARE-TIMI 58 Trial, a Large Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

FARXIGA met the primary composite endpoint of a statistically-significant reduction in hospitalization for heart failure or CV death in a broad patient population Results confirmed the well-established safety profile of FARXIGA AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (C...

ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018

ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the Leerink Partners Roundtable Series on October 2, 2018, at 8:00am ET at the ...

ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the Cantor Global Healthcare Conference on October 1, 2018, at 2:55pm ET at the InterContinental New York Barclay Hotel in New York City. The live webcast of the pres...

Montecito Medical Acquires Central Minnesota Medical Office Building

Montecito Medical, a premier owner of medical office properties throughout the United States, has completed the acquisition of a Class A medical office building in Willmar, Minnesota, that houses one of the region’s leading specialty providers. With over 360 lakes, Willmar is known for its thriving arts scene, exceptional school districts and gr...

Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Monday, October 1, 2018 at 10:40 a.m. Eastern Time in New York, NY....

Digital Realty to Acquire 424 Acres in Loudoun County, Virginia

SAN FRANCISCO, Sept. 24, 2018 /PRNewswire/ -- Digital Realty (NYSE: DLR), a leading global provider of data center, colocation and interconnection solutions, announced today it Read more...

Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced the appointment of Damien Monaghan, Quality Director, reporting to Finb...

Novartis plans to file for new Lucentis indication in ROP

ROP is a rare and potentially blinding resulted due to abnormal development of retinal blood vessels in premature babies. The company has presented data from a Rainbow phase The post Novartis plans to file for new Lucentis indication in ROP appeared first on Pharma Business review.

Attorney Stephanie A. Bogue joins Gilmore & Bell

Gilmore & Bell, P.C., a leading public finance law firm, is pleased to announce that Stephanie A. Bogue has joined the Firm as an associate attorney in the St. Louis office. Stephanie was admitted to the Missouri Bar in 2018 after graduating from the Saint Louis University School of Law (magna cum laude). During law school, Ms. Bogue won six A...

Attorney Laura E. Connor joins Gilmore & Bell

Gilmore & Bell, P.C., a leading public finance law firm, is pleased to announce that Laura E. Connor has joined the Firm as an associate attorney in the Kansas City office. Laura was admitted to the Missouri Bar in 2018. She received her B.A. degree from the University of Missouri in 2015 and her J.D. (magna cum laude) from the University of M...

DermTech Announces Publication of “Non-Invasive Gene Expression Testing to Rule Out Melanoma”

DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the publication of “Non-Invasive Gene Expression Testing to Rule Out Melanoma,” by Dr. Jason Rivers of the Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, and colleagues in Skin Therapy Letter. The manuscr...

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

• First-to-market cell line-derived reference standard for myeloid blood cancers • Largest cell-line derived reference standard available, contains 22 mutations across 19 oncology-relevant genes • Enables faster, more reliable and more cost-effective assay validation Cambridge, UK, 24 September, 2018: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “t...

Excelera® Specialty Pharmacy Network Announces Partnership with Smith & Nephew

ExceleraRx Corp. announced a partnership with Smith & Nephew for advanced wound care management products used in the treatment of acute and chronic wounds. These products will be made available through Excelera to health system specialty pharmacies. MINNEAPOLIS (PRWEB) September 24, 2018 The Excelera network consists of point-of-care specialty pharmacies owned by health systems and academic m...

Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients

Mechelen, Belgium, September 24 2018, 07.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing in the global ROCCELLA Phase 2 trial with GLPG1972/S201086 in knee osteoarthritis patients. Galapagos receives a €9 million milestone payment from its collaboration partner Servier for this achievement. ROCCELLA is a multiregional, randomized, double-blind, placebo-co...

Harris Personal Injury Lawyers, Inc. Sues City of San Francisco Following Bicycle Accident

Harris Personal Injury Lawyers, Inc. represents woman who sustained severe injuries due to cycling over an allegedly defective street car track in San Francisco. SAN FRANCISCO (PRWEB) September 24, 2018 Harris Personal Injury Lawyers, Inc. filed a complaint April 13, 2018 in San Francisco County Superior Court against the City and County of San Francisco, San Francisco Municipal Transportation Ag...

Karolinska Development AB (publ): Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is i...

4D pharma plc: 4D Announces Positive Data From Phase 1b Study of Thetanix in Paediatric Crohn's Diseases Patients and Publication of Studies Showing Strong Efficacy of Thetanix in Preclinical Models of IBD

LEEDS, United Kingdom, Sept. 24, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces positive top-line resu...

Cytox Expands Collaboration with AIBL to Identify Those Most at Risk to Rapidly Progress to Alzheimer’s

Important research collaboration for pioneering PRS approach to help drug developers running clinical trials identify and stratify between slow and rapid progressors of the disease Cytox, a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches fo

Sunday 23rd September 2018

NanoSpeed Diagnostics Inc Product Pipeline Analysis, 2018 Update [Report Updated: 29062018] Prices from USD $750

SummaryNanoSpeed Diagnostics Inc NanoSpeed is a medical device company that manufactures, designs, and develops self diagnostic and screening test kits. The company offers products such as test4Fe, test4D, test4Ca, and labonachip products, among others. Its test4Ca is used for testing calcium levels and test4Fe is used for testing iron levels. NanoSpeed' pointofcare testing platforms allow patient...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks